ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Price, Quote, News and Overview
NASDAQ:ARQT - Nasdaq - US03969K1088 - Common Stock - Currency: USD
ARQT Quote, Performance and Key Statistics
13.02
-0.4 (-2.98%)
The current stock price of ARQT is 13.02 USD. In the past month the price decreased by -4.26%. In the past year, price increased by 34.5%.
ARQT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ARQT
Company Profile
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 296 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Company Info
ARCUTIS BIOTHERAPEUTICS INC
3027 Townsgate Road, Suite 300
Westlake Village CALIFORNIA 91361 US
CEO: Todd Franklin Watanabe
Employees: 296
Company Website: https://arcutis.com/
Investor Relations: https://investors.arcutis.com/
Phone: 18054185006
ARCUTIS BIOTHERAPEUTICS INC / ARQT FAQ
What is the stock price of ARCUTIS BIOTHERAPEUTICS INC today?
The current stock price of ARQT is 13.02 USD. The price decreased by -2.98% in the last trading session.
What is the ticker symbol for ARCUTIS BIOTHERAPEUTICS INC stock?
The exchange symbol of ARCUTIS BIOTHERAPEUTICS INC is ARQT and it is listed on the Nasdaq exchange.
On which exchange is ARQT stock listed?
ARQT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARCUTIS BIOTHERAPEUTICS INC stock?
14 analysts have analysed ARQT and the average price target is 19.89 USD. This implies a price increase of 52.76% is expected in the next year compared to the current price of 13.02. Check the ARCUTIS BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARCUTIS BIOTHERAPEUTICS INC worth?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) has a market capitalization of 1.52B USD. This makes ARQT a Small Cap stock.
How many employees does ARCUTIS BIOTHERAPEUTICS INC have?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) currently has 296 employees.
What are the support and resistance levels for ARCUTIS BIOTHERAPEUTICS INC (ARQT) stock?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) has a support level at 11.72 and a resistance level at 13.43. Check the full technical report for a detailed analysis of ARQT support and resistance levels.
Is ARCUTIS BIOTHERAPEUTICS INC (ARQT) expected to grow?
The Revenue of ARCUTIS BIOTHERAPEUTICS INC (ARQT) is expected to grow by 222.23% in the next year. Check the estimates tab for more information on the ARQT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARCUTIS BIOTHERAPEUTICS INC (ARQT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARQT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARQT, evaluating the profitability, health, valuation and growth aspects
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Sales and EPS estimates to see what analysts future expectations are.
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Chart to make your own analysis
- ARCUTIS BIOTHERAPEUTICS INC (ARQT) Latest news and press-releases to stay up to date.
Does ARCUTIS BIOTHERAPEUTICS INC (ARQT) stock pay dividends?
ARQT does not pay a dividend.
When does ARCUTIS BIOTHERAPEUTICS INC (ARQT) report earnings?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) will report earnings on 2025-02-25, after the market close.
What is the Price/Earnings (PE) ratio of ARCUTIS BIOTHERAPEUTICS INC (ARQT)?
ARCUTIS BIOTHERAPEUTICS INC (ARQT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.79).
What is the Short Interest ratio of ARCUTIS BIOTHERAPEUTICS INC (ARQT) stock?
The outstanding short interest for ARCUTIS BIOTHERAPEUTICS INC (ARQT) is 18.13% of its float. Check the ownership tab for more information on the ARQT short interest.
ARQT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ARQT. When comparing the yearly performance of all stocks, ARQT is one of the better performing stocks in the market, outperforming 90.71% of all stocks.
ARQT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARQT. Both the profitability and financial health of ARQT have multiple concerns.
ARQT Financial Highlights
Over the last trailing twelve months ARQT reported a non-GAAP Earnings per Share(EPS) of -1.79. The EPS increased by 59.13% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.71% | ||
| ROE | -124.83% | ||
| Debt/Equity | 0.67 |
ARQT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ARQT. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 65.59% and a revenue growth 222.23% for ARQT